Chelonian Conservation And Biology

Vol. 19No.1 (2024) | https://www.acgpublishing.com/ | ISSN - 1071-8443

DOI:doi.org/10.18011/2024.01(1). 1371-1375

STUDYING METHODS TO MONITOR AND EVALUATE THE SAFETY OF DRUGS POST-MARKET, INCLUDING ADVERSE DRUG REACTIONS

Mohammed Nuwaymi Toma Aljaberi[1]*, Asma Ibrahim Al Zayn[2], Talal Tail Alsulami[3], Mohammad Saleh Abdullah Alamri[4], Saad Mohammed Awwadh Alshalwi[5], Fahad Noor Faleh Alasadi[6], Nader Essa Subayyil Alotaibi[7] and Ali Abdullah Ahmed Alqarni[8]

1* Corresponding Author, Pharmacist, King Fahad Armed Forces Hospital
2 Pharmacist, King Fahad Armed Forces Hospital
3 Technician pharmacy, King Fahad Armed Forces Hospital
4 Technician pharmacy, King Fahad Armed Forces Hospital
5 Pharmacy technician, King Fahad Armed Forces Hospital
6 Technician pharmacy, King Fahad armed forces hospital
7 Technician pharmacy, King Fahad armed forces hospital
8 Technician pharmacy, King Fahad armed forces hospital

Abstract:

The safety of drugs post-market is a crucial aspect that must be carefully monitored and evaluated to ensure the well-being of patients. Adverse drug reactions (ADRs) can have serious consequences, and it is important to have effective methods in place to detect, assess, and manage these reactions. This paper explores various studying methods used to monitor and evaluate the safety of drugs post-market, with a specific focus on adverse drug reactions. The methodology, results, and discussion of these methods are presented to provide a comprehensive overview of the topic.

Keywords: drugs, safety, monitoring, evaluation, adverse drug reactions

Introduction:

The development and approval of a new drug is a lengthy and complex process that involves rigorous testing to ensure its safety and efficacy. However, even after a drug has been approved for use, it is important to continue monitoring its safety in the real-world setting. This is because clinical trials may not detect all potential adverse effects of a drug due to their limited sample size and duration.

Adverse drug reactions (ADRs) are unintended and harmful reactions that occur in response to a drug. These reactions can range from mild to severe, and in some cases, can even be life-

threatening. It is estimated that ADRs are responsible for a significant number of hospital admissions and deaths each year, making them a major public health concern.

Monitoring and evaluating the safety of drugs post-market involves the systematic collection, analysis, and interpretation of data related to adverse reactions. Various studying methods are used for this purpose, including pharmacovigilance, pharmacoepidemiology, and signal detection. These methods play a crucial role in detecting and assessing ADRs, identifying potential safety issues, and informing regulatory decisions.

Studying methods to monitor and evaluate the safety of drugs post-market, including adverse drug reactions (ADRs), is crucial for ensuring patient safety and optimizing the use of medications. Here are some approaches and methodologies commonly used in pharmacovigilance, the science of monitoring and assessing drug safety after market approval:

Spontaneous Reporting Systems:

Adverse Event Reporting: Health professionals, patients, and pharmaceutical companies report ADRs to regulatory authorities or drug manufacturers.

Signal Detection: Statistical methods and data mining techniques are used to identify potential safety signals from reported adverse events.

Electronic Health Records (EHRs):

Data Mining: Analyzing structured and unstructured data from electronic health records to identify potential ADRs and trends.

Natural Language Processing: Using algorithms to extract and analyze information from clinical notes and narratives in EHRs.

Pharmaceutical Company Databases:

Pharmacovigilance Databases: Pharmaceutical companies maintain databases of reported adverse events and conduct internal safety assessments.

Risk Management Plans: Companies develop risk management plans to identify, characterize, and mitigate risks associated with their products.

Registries and Observational Studies:

Patient Registries: Collecting real-world data on drug use and outcomes to monitor long-term safety and effectiveness.

Post-Authorization Safety Studies (PASS): Conducting observational studies to assess the safety of drugs in routine clinical practice.

Meta-Analysis and Systematic Reviews:

Pooling Data: Combining results from multiple studies to evaluate the overall safety profile of a drug.

Quantitative Synthesis: Using statistical methods to analyze and summarize safety data from various sources.

Risk Evaluation and Mitigation Strategies (REMS):

Risk Minimization: Implementing strategies to manage known or potential risks associated with a drug, such as restricted distribution programs or education initiatives.

Evaluation: Assessing the effectiveness of REMS in mitigating risks and improving drug safety.

Data Linkage and Data Integration:

Database Linkage: Connecting different databases to link drug exposure data with health outcomes for comprehensive safety assessments.

Data Integration: Combining data from multiple sources to enhance signal detection and risk assessment.

By employing these methods and approaches, researchers, regulatory agencies, healthcare providers, and pharmaceutical companies can effectively monitor and evaluate the safety of drugs post-market, identify potential risks, and take appropriate measures to protect patient health.

Methodology:

Pharmacovigilance is a key component of drug safety monitoring and involves the continuous monitoring of adverse reactions to drugs. This includes the collection of data from healthcare providers, patients, and other sources, as well as the analysis of this data to identify potential safety concerns. Pharmacovigilance data can come from a variety of sources, including spontaneous reporting systems, electronic health records, and clinical trials.

Pharmacoepidemiology is another important method used to monitor the safety of drugs post-market. This discipline focuses on the study of the use and effects of drugs in large populations. Pharmacoepidemiologic studies can help identify risk factors for ADRs, evaluate the effectiveness of risk management strategies, and assess the impact of drug safety policies.

Signal detection is a method used to identify potential safety issues associated with a drug. Signals can be detected through various means, such as data mining techniques, statistical analyses, and expert review. Once a signal is detected, further investigation is needed to confirm the existence of a safety concern and determine the appropriate regulatory action.

Results:

The results of pharmacovigilance, pharmacoepidemiology, and signal detection studies can provide valuable insights into the safety of drugs post-market. These studies have helped identify and characterize a wide range of adverse reactions associated with various drugs, ranging from common side effects to rare but serious events.

For example, pharmacovigilance data has been instrumental in detecting safety issues with drugs such as rofecoxib (Vioxx) and rosiglitazone (Avandia), leading to their withdrawal from the market. Pharmacoepidemiologic studies have provided important information on the risks of drug interactions, off-label use, and medication errors. Signal detection has helped identify emerging safety concerns with drugs such as dabigatran (Pradaxa) and varenicline (Chantix), leading to changes in their prescribing information.

Discussion:

The monitoring and evaluation of drug safety post-market is a complex and multifaceted process that requires the collaboration of multiple stakeholders, including regulators, healthcare providers, pharmaceutical companies, and patients. While progress has been made in this area, there are still challenges that need to be addressed to improve the detection and management of adverse reactions.

One key challenge is underreporting of ADRs, which can lead to delays in detecting safety issues and taking appropriate action. Healthcare providers may not always recognize or report ADRs, and patients may not be aware of the importance of reporting them. Efforts are needed to raise awareness about the importance of pharmacovigilance and encourage reporting of ADRs.

Another challenge is the lack of standardization in the collection and reporting of pharmacovigilance data. Different countries and organizations may use different methods and terminology, making it difficult to compare and analyze data across different sources. Standardizing data collection and reporting practices can help improve the quality and reliability of pharmacovigilance data.

Concussion:

In conclusion, studying methods to monitor and evaluate the safety of drugs post-market, including adverse drug reactions, is essential for ensuring the well-being of patients. Pharmacovigilance, pharmacoepidemiology, and signal detection are important tools that can help detect and assess ADRs, identify potential safety issues, and inform regulatory decisions. By addressing challenges such as underreporting and lack of standardization, we can improve the effectiveness of drug safety monitoring and ultimately enhance patient safety.

References:

1. World Health Organization. The importance of pharmacovigilance: safety monitoring of medicinal products. https://www.who.int/medicines/areas/quality_safety/safety_efficacy/pharmacovigilance/en/
2. Van Puijenbroek EP, Bate A, Leufkens HG, Lindquist M, Orre R, Egberts AC. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002;11(1):3-10.
3. FDA. Drug safety information: monitoring and evaluating drug safety. https://www.fda.gov/drugs/drug-information-consumers/drug-safety-and-availability
4. Strom BL, Kimmel SE, Hennessy S. Pharmacoepidemiology. John Wiley & Sons; 2019.
5. Wisniewski AF, Bate A, Bousquet C, et al. Good signal detection practices: evidence from IMI PROTECT. Drug Saf. 2016;39(6):469-90.
6. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals for prescription medications. JAMA. 2002;287(17):2215-20.
7. Moore TJ, Cohen MR, Furberg CD. Serious adverse drug events reported to the Food and Drug Administration, 1998-2005. Arch Intern Med. 2007;167(16):1752-9.
8. Coloma PM, Trifirò G, Schuemie MJ, et al. Electronic healthcare databases for active drug safety surveillance: is there enough leverage? Pharmacoepidemiol Drug Saf. 2012;21(6):611-21.
9. European Medicines Agency. Good pharmacovigilance practices. https://www.ema.europa.eu/en/human-regulatory/post-authorisation/pharmacovigilance/good-pharmacovigilance-practices
10. Baker EL. Pharmacoepidemiology. South Med J. 2008;101(3):305-9.